Eloxx Pharmaceuticals (ELOX) demoted by Zacks Investment Research

Eloxx Pharmaceuticals (OTCMKTS: ELOX) from a rating of One-Sale Retention »According to Zacks," Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule drugs to treat many rare and ultra-rare genetic diseases. "The company's lead product candidate, ELX -02, is an optimized aminoglycoside designed to restore full-length functional proteins, mainly in Waltham, MA and Rehovot, Israel Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, USA. United States. "

Several other equity research badysts have also recently taken a stand on the company." Piper Jaffray Companies has taken over El oxx Pharmace in a report on Tuesday, May 1st. They issued an overweight and a price target of $ 20.00 for the company. SunTrust Banks took over coverage of Eloxx Pharmaceuticals in a report on Monday, June 25. They issued a purchase note and a price target of $ 26.00 for the company. Canaccord Genuity took over coverage of Eloxx Pharmaceuticals in a report on Friday, June 29. They issued a purchase note and a price target of $ 24.00 for the company. Finally, Citigroup initiated a hedge on Eloxx Pharmaceuticals in a report on Tuesday, July 3. They issued a purchase note and a price target of $ 31.00 for the company. An investment badyst has badigned a rating to the stock and four have awarded a note to buy the company's stock. The stock has an average buy score and a consensus target price of $ 25.25.

Eloxx Pharmaceuticals shares were depreciated by $ 0.91 during trading on Tuesday, reaching $ 15.76. 49,598 shares were exchanged for an average volume of 98,592 shares. Eloxx Pharmaceuticals has a 52-week low of $ 3.62 and a high of $ 52 from $ 24.60 in 52 weeks.

Eloxx Pharmaceuticals (OTCMKTS: ELOX) last published its quarterly results on Thursday, May 10th. The company reported ($ 0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($ 0.22) from ($ 0.09).

By the way, the main shareholder, Gilad Shabtai, acquired 75,000 shares of the company during an operation that occurred on Monday, April 30th. The stock was purchased at an average price of $ 9.75 per share, for a total value of $ 731,250.00. The purchase was disclosed in a legal deposit with the Securities & Exchange Commission, which is available on the SEC's website. In addition, CEO Robert Ward acquired 5,000 corporate shares during an operation on Tuesday, May 22. The stock was purchased at an average cost of $ 14.34 per share, for a total value of $ 71,700.00. The disclosure for this purchase can be found here. Over the past three months, insiders have acquired 430,000 shares valued at $ 4,215,450. Corporate insiders own 44.03% of the shares of the company.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of diseases early and rare. Its main program is ELX-02, which is in a Phase I clinical trial, which focuses on treating patients with cystic fibrosis and cystinosis with diagnosed nonsense mutations.

Recommended History: How to Invest in Growth Stocks

Get a free copy of the Zacks Research Report on Eloxx Pharmaceuticals (ELOX)

For more information on the research offers of Zacks Investment Research, visit Zacks.com

Receive News & Reviews for Eloxx Daily Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and badyst ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's free daily e-newsletter.